Bockhorn Maximilian, Cataldegirmen Guellue, Kutup Asad, Marx Andreas, Burdelski Christoph, Vashist Jogesh K, Mann Oliver, Liebl Lena, König Alexandra, Izbicki Jakob R, Yekebas Emre F
Department of General, Visceral and Thoracic Surgery, University Medical Centre Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
Ann Surg Oncol. 2009 May;16(5):1212-21. doi: 10.1245/s10434-009-0363-2. Epub 2009 Feb 19.
To analyze the impact of pancreatitis-mimicking, concomitant alterations on intraoperative assessment of curative resectability, the anatomical site of irresectability, and outcome after nonintentional R2 resection in pancreatic cancer.
Of 1,099 patients subjected to pancreatic resection for cancer, 40 (4%) underwent R2 resection (group A). The site where tumors turned out to be irresectable and the coincident presence of potentially misleading, fibro-desmoplastic alterations were analyzed. Outcome after resection was compared with 40 bypass patients matched for age, gender, histopathology, and use of additive chemotherapy (group B).
R2 resection was due to misjudgment regarding resectability in 38 patients (95%) and to uncontrollable hemorrhage in 2 patients (5%). Group A patients had significantly longer operative times (P < 0.0001), required more blood units (P < 0.0001), and had longer hospital stay than group B patients (P = 0.049). Despite a significantly higher relaparotomy rate of 20% (n = 8) in group A versus 5% (n = 2) in group B, perioperative mortality was equal (n = 2, each). Median survival was 11.5 months in group A and 7.5 months in group B (P = 0.014). "Pancreatitis-like" lesions were assessed in 70% (n = 28/40, group A) and 25% (10/40, group B; P = 0.014). The superior mesenteric artery proximal to its jejunal branches was the most likely site of irresectability (60%), followed by its peripheral course (22.5%) and the lower aspects of the celiac trunk (17.5%).
Concomitant "pancreatitis-like" alterations hamper the assessment of local resectability in pancreatic cancer. Although palliative resection results in elevated perioperative morbidity compared with bypass procedures, mortality is equal, while survival is prolonged.
分析类似胰腺炎的伴随性改变对胰腺癌根治性可切除性的术中评估、不可切除的解剖部位以及非计划性R2切除术后结局的影响。
在1099例行胰腺癌切除术的患者中,40例(4%)接受了R2切除(A组)。分析肿瘤不可切除的部位以及同时存在的可能产生误导的纤维结缔组织增生性改变。将切除术后的结局与40例在年龄、性别、组织病理学和辅助化疗使用方面相匹配的行旁路手术的患者进行比较(B组)。
38例患者(95%)的R2切除是由于对可切除性判断错误,2例患者(5%)是由于无法控制的出血。A组患者的手术时间明显更长(P<0.0001),需要更多单位的血液(P<0.0001),住院时间也比B组患者更长(P=0.049)。尽管A组的再次剖腹手术率显著高于B组,分别为20%(n=8)和5%(n=2),但围手术期死亡率相同(每组n=2)。A组的中位生存期为11.5个月,B组为7.5个月(P=0.014)。70%(n=28/40,A组)和25%(10/40,B组;P=0.014)的患者存在“胰腺炎样”病变。肠系膜上动脉空肠分支近端是最常见的不可切除部位(60%),其次是其外周走行部位(22.5%)和腹腔干下部(17.5%)。
伴随的“胰腺炎样”改变会妨碍对胰腺癌局部可切除性的评估。尽管与旁路手术相比,姑息性切除会导致围手术期发病率升高,但死亡率相同,而生存期延长。